This Title All WIREs
How to cite this WIREs title:
WIREs Nanomed Nanobiotechnol
Impact Factor: 6.14

Metal‐based nanoparticle interactions with the nervous system: the challenge of brain entry and the risk of retention in the organism

Full article on Wiley Online Library:   HTML PDF

Can't access this content? Tell your librarian.

Abstract This review of metal‐based nanoparticles focuses on factors influencing their distribution into the nervous system, evidence they enter brain parenchyma, and nervous system responses. Gold is emphasized as a model metal‐based nanoparticle and for risk assessment in the companion review. The anatomy and physiology of the nervous system, basics of colloid chemistry, and environmental factors that influence what cells see are reviewed to provide background on the biological, physical–chemical, and internal milieu factors that influence nervous system nanoparticle uptake. The results of literature searches reveal little nanoparticle research included the nervous system, which about equally involved in vitro and in vivo methods, and very few human studies. The routes of uptake into the nervous system and mechanisms of nanoparticle uptake by cells are presented with examples. Brain nanoparticle uptake inversely correlates with size. The influence of shape has not been reported. Surface charge has not been clearly shown to affect flux across the blood‐brain barrier. There is very little evidence for metal‐based nanoparticle distribution into brain parenchyma. Metal‐based nanoparticle disruption of the blood‐brain barrier and adverse brain changes have been shown, and are more pronounced for spheres than rods. Study concentrations need to be put in exposure contexts. Work with dorsal root ganglion cells and brain cells in vitro show the potential for metal‐based nanoparticles to produce toxicity. Interpretation of these results must consider the ability of nanoparticles to distribute across the barriers protecting the nervous system. Effects of the persistence of poorly soluble metal‐based nanoparticles are of particular concern. WIREs Nanomed Nanobiotechnol 2013, 5:346–373. doi: 10.1002/wnan.1202 This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials

This WIREs title offers downloadable PowerPoint presentations of figures for non-profit, educational use, provided the content is not modified and full credit is given to the author and publication.

Download a PowerPoint presentation of all images

Interfacial double layers near colloidal particles. Collodial particle = gray sphere. Positive ions are shown in pink. Negative ions are shown in blue.

[ Normal View | Magnified View ]

Influence of nanoparticle (NP) size on brain uptake. (a)–(e) The percentage of gold NP dose in rat or mouse brain. (f) and (g) The percentage of the gold NP dose taken up into rat primary brain microvascular endothelial cells (BMECs) per mg protein. (h) The percentage of the gold NP dose that permeated through rat BMECs. Asterisks indicate NP sizes that were * not detectible, ** below control, or *** reported as 0. The ζ potential of the PEG‐coated gold NPs was approximately −2 to −11 mV. The dendrimers were an acetamide poly(amido amine) (PAMAM). Uptake in rat BMECs was conducted with primary cells. Rat brain permeation was through an endothelial and astrocyte cell coculture.

[ Normal View | Magnified View ]

Nanoparticle (NP) distribution into the brain, expressed as a percentage of the dose and time after NP administration. Red: Unable to find the NP in the brain or reported that it was not in the brain. Black: Brain NP can be attributed to its presence in the brain's vascular compartment and the report provides no evidence of NP distribution into brain parenchyma. Blue: Brain NP is too high to be attributed to its presence in the brain's vascular compartment but the report provides no evidence of NP distribution into brain parenchyma, so the NP could have been associated with blood‐brain barrier (BBB) cells but did not enter brain parenchyma. Green: The report provides evidence of NP distribution into brain parenchyma.

[ Normal View | Magnified View ]

Global nanoparticle (NP) patent activity for all NPs and selected metal‐based NPs.

[ Normal View | Magnified View ]

Results of SciFinder searches of (a) all publications of Nanoparticles (NPs) and those using in vitro and in vivo study platforms, (b) metal‐based NP nervous system publications by metal, and (c) metal‐based NP nervous system studies by research platform.

[ Normal View | Magnified View ]

Related Articles

Assessing nanoparticle risk poses prodigious challenges
Physicochemical factors that affect metal and metal oxide nanoparticle passage across epithelial barriers
Pharmacokinetics of nanomaterials: an overview of carbon nanotubes, fullerenes and quantum dots
Special Topics in Nanomedicine and Nanobiotechnology

Browse by Topic

Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease
Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts